Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Metastatic Anal Cancer
NCT02919969Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2016
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in anal cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response Rate at 12.6 months. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT02919969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919969.